A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma

Abstract

BackgroundTreatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.MethodsONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient‐reported quality of life were analyzed.ResultsFourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in‐field radiographic progression, five patients (38%) experienced progression in non‐contiguous dura. Two‐year local control was 85% (95% CI: 51–96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.ConclusionIn this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.